S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NYSE:MCK

McKesson (MCK) Stock Forecast, Price & News

$387.95
-7.44 (-1.88%)
(As of 05/26/2023 07:00 PM ET)
Compare
Today's Range
$387.53
$397.59
50-Day Range
$335.83
$400.96
52-Week Range
$298.69
$401.78
Volume
800,000 shs
Average Volume
982,747 shs
Market Capitalization
$52.61 billion
P/E Ratio
15.45
Dividend Yield
0.56%
Price Target
$430.17

McKesson MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
10.9% Upside
$430.17 Price Target
Short Interest
Healthy
1.35% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
-0.30mentions of McKesson in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$7.16 M Sold Last Quarter
Proj. Earnings Growth
14.46%
From $26.56 to $30.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

68th out of 1,010 stocks

Drugs, Proprietaries, & Sundries Industry

2nd out of 7 stocks


MCK stock logo

About McKesson (NYSE:MCK) Stock

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment br

Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Stock News Headlines

McKesson Stock Approaching New Highs As Bullish Trend Continues
Healthcare products distributor McKesson is nearing new highs with a bullish trend. In Q4, the company beat views on both the top and bottom lines.
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Advancing the Future of Cancer Care
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Mckesson $MCK Trading Report
See More Headlines
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Company Calendar

Ex-Dividend for 4/3 Dividend
2/28/2023
Dividend Payable
4/03/2023
Last Earnings
5/08/2023
Today
5/29/2023
Ex-Dividend for 7/3 Dividend
5/31/2023
Dividend Payable
7/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Sector
Medical
CUSIP
58155Q10
Employees
51,000
Year Founded
1833

Price Target and Rating

Average Stock Price Forecast
$430.17
High Stock Price Forecast
$475.00
Low Stock Price Forecast
$390.00
Forecasted Upside/Downside
+10.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$3.56 billion
Pretax Margin
1.67%

Debt

Sales & Book Value

Annual Sales
$276.71 billion
Cash Flow
$32.22 per share
Book Value
($10.99) per share

Miscellaneous

Free Float
135,317,000
Market Cap
$52.61 billion
Optionable
Optionable
Beta
0.58

Social Links


Key Executives

  • Brian Scott TylerBrian Scott Tyler
    Chief Executive Officer & Director
  • Britt J. VitaloneBritt J. Vitalone
    Chief Financial Officer & Executive Vice President
  • Nancy Avila
    Chief Technology & Information Officer, EVP
  • Lori A. SchechterLori A. Schechter
    Chief Legal Officer, EVP & General Counsel
  • Tom Rodgers
    Chief Strategy & Business Development Officer, EVP













MCK Stock - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCK shares.
View MCK analyst ratings
or view top-rated stocks.

What is McKesson's stock price forecast for 2023?

9 Wall Street research analysts have issued 1-year target prices for McKesson's stock. Their MCK share price forecasts range from $390.00 to $475.00. On average, they anticipate the company's share price to reach $430.17 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price.
View analysts price targets for MCK
or view top-rated stocks among Wall Street analysts.

How have MCK shares performed in 2023?

McKesson's stock was trading at $375.12 at the beginning of the year. Since then, MCK stock has increased by 3.4% and is now trading at $387.95.
View the best growth stocks for 2023 here
.

When is McKesson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MCK earnings forecast
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) announced its earnings results on Monday, May, 8th. The company reported $7.19 earnings per share for the quarter, topping the consensus estimate of $7.16 by $0.03. The business earned $68.91 billion during the quarter, compared to analyst estimates of $67.94 billion. McKesson had a net margin of 1.29% and a negative trailing twelve-month return on equity of 234.22%. McKesson's revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm earned $5.83 earnings per share.
Read the conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson declared a quarterly dividend on Thursday, April 27th. Stockholders of record on Thursday, June 1st will be paid a dividend of $0.54 per share on Monday, July 3rd. This represents a $2.16 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Wednesday, May 31st.
Read our dividend analysis for MCK
.

Is McKesson a good dividend stock?

McKesson (NYSE:MCK) pays an annual dividend of $2.16 per share and currently has a dividend yield of 0.56%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 8.60%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MCK will have a dividend payout ratio of 7.11% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MCK.

What guidance has McKesson issued on next quarter's earnings?

McKesson updated its FY 2024 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $26.10-$26.90 for the period, compared to the consensus estimate of $26.33. The company issued revenue guidance of $287.78 billion-$301.62 billion, compared to the consensus revenue estimate of $286.63 billion.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson Chief Executive Officer Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among the company's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.32%), State Street Corp (4.66%), Price T Rowe Associates Inc. MD (2.36%), FMR LLC (1.97%), Geode Capital Management LLC (1.82%) and Berkshire Hathaway Inc (1.69%). Insiders that own company stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Lori A Schechter, Lori A Schechter, Marie L/Ca Knowles, Nancy Avila, Nancy Flores, Sundeep G Reddy, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends
.

How do I buy shares of McKesson?

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $387.95.

How much money does McKesson make?

McKesson (NYSE:MCK) has a market capitalization of $52.61 billion and generates $276.71 billion in revenue each year. The company earns $3.56 billion in net income (profit) each year or $25.11 on an earnings per share basis.

How many employees does McKesson have?

The company employs 51,000 workers across the globe.

Does McKesson have any subsidiaries?
The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More
How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The official website for the company is www.mckesson.com. The company can be reached via phone at (972) 446-4800, via email at investors@mckesson.com, or via fax at 415-983-8453.

This page (NYSE:MCK) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -